3-(1H-imidazol-1-yl)-6-(4-phenoxypiperidin-1-yl)pyridazine | 1208485-36-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(1H-imidazol-1-yl)-6-(4-phenoxypiperidin-1-yl)pyridazine
• 英文别名: 3-imidazol-1-yl-6-(4-phenoxypiperidin-1-yl)pyridazine
• CAS: 1208485-36-2
• 化学式: C₁₈H₁₉N₅O
• 分子量: 321.382
• InChiKey: LIYFZZZVGPYDSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  56.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(6-(1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-ol 、 苯酚 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 3-(1H-imidazol-1-yl)-6-(4-phenoxypiperidin-1-yl)pyridazine
  参考文献：
  名称：

  Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)

  摘要：

  A series of stearoyl-CoA desaturase 1 (SCD1) inhibitors were developed. Investigations of enzyme potency and metabolism led to the identification of the thiadiazole-pyridazine derivative MF-438 as a potent SCD1 inhibitor. MF-438 exhibits good pharmacokinetics and metabolic stability, thereby serving as a valuable tool for further understanding the role of SCD inhibition in biological and pharmacological models of diseases related to metabolic disorders. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.111

文献信息

• Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)
  作者：Serge Léger、W. Cameron Black、Denis Deschenes、Sarah Dolman、Jean-Pierre Falgueyret、Marc Gagnon、Sébastien Guiral、Zheng Huang、Jocelyne Guay、Yves Leblanc、Chun-Sing Li、Frédéric Massé、Renata Oballa、Lei Zhang

  DOI：10.1016/j.bmcl.2009.11.111

  日期：2010.1

  A series of stearoyl-CoA desaturase 1 (SCD1) inhibitors were developed. Investigations of enzyme potency and metabolism led to the identification of the thiadiazole-pyridazine derivative MF-438 as a potent SCD1 inhibitor. MF-438 exhibits good pharmacokinetics and metabolic stability, thereby serving as a valuable tool for further understanding the role of SCD inhibition in biological and pharmacological models of diseases related to metabolic disorders. (C) 2009 Elsevier Ltd. All rights reserved.